


Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

Panayiotis D. Ziakas

Bone Marrow Transplantation Unit, "Hygeia" Diagnostic & Therapeutic Centre, Athens, Greece

Citation: Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. *Haematologica* 2008. doi: 10.3324/haematol.12970



Supplementary Table S2. Effect of JAK2 V617F on venous thrombosis (a), arterial thrombosis (b) and thrombosis at presentation (c). Data pooled from 1330, 1330 and 1285 ET patients, respectively.

Appendix

- Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet*. 2005;365:1054-61.
- Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al; United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. *Lancet*. 2005;366:1945-53.
- Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. *Br J Haematol*. 2005;131:208-13.
- Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. *Br J Haematol*. 2006;132:244
- Heller PG, Lev PR, Salim JP, Kornblit LI, Goette NP, Chazarreta CD, et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. *Eur J Haematol*. 2006;77:210-6.
- Stevenson WS, Hoyt R, Bell A, Guipponi M, Juneja S, Grigg AP, et al. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. *Pathology* 2006;38:336-42.
- Alvarez-Larrán A, Cervantes F, Bellosillo B, Giral M, Juliá A, Hernández-Boluda JC, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. *Leukemia*. 2007;21:1218-23.
- Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythaemia vera according to JAK2 V617F mutation status.

- *Haematologica* 2007;92:135-6.
- Hsiao HH, Yang MY, Liu YC, Lee CP, Yang WC, Liu TC, et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. *Exp Hematol*. 2007;35:1704-7
- Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. *Cancer*. 2007;109:2279-84.
- Ohyashiki K, Ito Y, Hori K, Sato K, Makino T, Ohyashiki JH. Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan. *Leukemia*. 2007;21:1570-1.
- Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. *Leukemia*. 2007;21:2210-2
- Rudzki Z, Sacha T, Stój A, Czekalska S, Wójcik M, Skotnicki AB, et al. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocytic": a molecular, histologic, and clinical study. *Int J Hematol*. 2007;86:130-6.
- Speletas M, Katodritou E, Daiou C, Mandala E, Papadakis E, Kioumi A et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. *Leuk Res*. 2007;31:1053-62.
- Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T, et al. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. *Br J Haematol*. 2007;139:64-9.
- Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 V617F mutation in patients with polycythaemia vera or essential thrombocythemia. *Blood*. 2007;110:840-6.
- Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Myeloproliferative Disorders Research Consortium (MPD-RC). Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. *Haematologica*. 2008;93:41-8.